Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: Targeting advantage of inhalational administration

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 5, 2014, Pages 2570-2579

  Yapa, Shalini W S ^a   Li, Jian ^a   Patel, Kashyap ^a   Wilson, John W ^b   Dooley, Michael J ^a,c   George, Johnson ^a   Clark, Denise ^b   Poole, Susan ^a,c   Williams, Elyssa ^b   Porter, Christopher J H ^a   Nation, Roger L ^a   McIntosh, Michelle P ^a  

^a MONASH UNIVERSITY   (Australia)

^b ALFRED HOSPITAL   (Australia)

^c Pharmacy Department   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

COLISTIMETHATE; COLISTIN; CREATININE; SALBUTAMOL; ANTIINFECTIVE AGENT; COLISTINMETHANESULFONIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HUMAN TISSUE; LIMIT OF QUANTITATION; LUNG FUNCTION TEST; MALE; MAXIMUM PLASMA CONCENTRATION; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SPUTUM ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION; URINALYSIS; YOUNG ADULT; AGED; ANALOGS AND DERIVATIVES; CHEMISTRY; CLINICAL TRIAL; FEMALE; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; MIDDLE AGED; SPUTUM; VERY ELDERLY;

ADMINISTRATION, INHALATION; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COLISTIN; CYSTIC FIBROSIS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; SPUTUM;

EID: 84898634072     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01705-13     Document Type: Article

References (40)

1. Hansen CR, Pressler T, Høiby N. 2008. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J. Cyst. Fibros. 7:523-530. http://dx.doi.org/10.1016/j.jcf.2008.06.009.
2. Döring G. 2010. Prevention of Pseudomonas aeruginosa infection in cystic fibrosis patients. Int. J. Med. Microbiol. 300:573-577. http://dx.doi.org/10.1016/j.ijmm.2010.08.010.
3. Høiby N, Ciofu O, Bjarnsholt T. 2010. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 5:1663-1674. http://dx.doi.org/ 10.2217/fmb.10.125.
4. Döring G, Conway SP, Heijerman HG, Hodson ME, Høiby N, Smyth A, Touw DJ. 2000. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur. Respir. J. 16:749-767. http://dx.doi.org/ 10.1034/j.1399-3003.2000.16d30.x.
5. Döring G, Høiby N, Consensus Study Group. 2004. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J. Cyst. Fibros. 3:67-91. http://dx.doi.org/10.1016/j.jcf.2004.03. 008.
6. Høiby N. 2011. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9:32. http://dx.doi.org/10. 1186/1741-7015-9-32.
7. Nation RL, Li J. 2009. Colistin in the 21st century. Curr. Opin. Infect. Dis. 22:535-543. http://dx.doi.org/10.1097/QCO.0b013e328332e672.
8. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. 2005. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria. Int. J. Antimicrob. Agents 25:11-25. http://dx.doi.org/10.1016/j.ijantimicag.2004.10. 001.
9. Bergen PJ, Li J, Rayner CR, Nation RL. 2006. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 50:1953-1958. http://dx.doi.org/10.1128/AAC.00035-06.
10. Banerjee D, Stableforth D. 2000. The treatment of respiratory Pseudomonas infection in cystic fibrosis: what drug and which way? Drugs 60:1053-1064. http://dx.doi.org/10.2165/00003495-200060050-00006.
11. Ledson MJ, Gallagher MJ, Cowperthwaite C, Convery RP, Walshaw MJ. 1998. Four years' experience of intravenous colomycin in an adult cystic fibrosis unit. Eur. Respir. J. 12:592-594. http://dx.doi.org/10.1183/09031936.98. 12030592.
12. Conway SP, Pond MN, Watson A, Etherington C, Robey HL, Goldman MH. 1997. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 52:987-993. http://dx.doi.org/10.1136/thx. 52.11.987.
13. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, Vishnepolsky M, Weintrob A, Wortmann G. 2009. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin. Infect. Dis. 48:1724-1728. http://dx.doi.org/10.1086/599225.
14. Westerman EM, De Boer AH, Le Brun PP, Touw DJ, Roldaan AC, Frijlink HW, Heijerman HG. 2007. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibros. 6:284-292. http://dx.doi.org/10.1016/j.jcf.2006.10.010.
15. Le Brun PP, de Boer AH, Mannes GP, de Fraîture DM, Brimicombe RW, Touw DJ, Vinks AA, Frijlink HW, Heijerman HG. 2002. Dry powder inhalation of antibiotics in cystic fibrosis therapy: part 2. Inhalation of a novel colistin dry powder formulation: a feasibility study in healthy volunteers and patients. Eur. J. Pharm. Biopharm. 54:25-32. http://dx.doi.org/10.1016/S0939-6411(02) 00044-9.
16. Ratjen F, Rietschel E, Kasel D, Schwiertz R, Starke K, Beier H, van Koningsbruggen S, Grasemann H. 2006. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother. 57:306-311. http://dx.doi.org/10.1093/jac/dki461.
17. Byrne N, Keavey P, Perry J, Gould F, Spencer D. 2003. Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis. Arch. Dis. Child. 88:715-718. http://dx.doi.org/10.1136/adc.88.8.715.
18. Le Brun PP, de Graaf AI, Vinks AA. 2000. High-performance liquid chromatographic method for the determination of colistin in serum. Ther. Drug Monit. 22:589-593. http://dx.doi.org/10.1097/00007691-200010000-00014.
19. Li J, Coulthard K, Milne R, Nation RL, Conway S, Peckham D, Etherington C, Turnidge J. 2003. Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. J. Antimicrob. Chemother. 52:987-992. http://dx.doi.org/10.1093/jac/dkg468.
20. Reed MD, Stern RC, O'Riordan MA, Blumer JL. 2001. The pharmacokinetics of colistin in patients with cystic fibrosis. J. Clin. Pharmacol. 41: 645-654. http://dx.doi.org/10.1177/00912700122010537.
21. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, Paterson DL. 2006. Colistin: the re-emerging antibiotic for multidrugresistant Gram-negative bacterial infections. Lancet Infect. Dis. 6:589-601. http://dx.doi.org/10.1016/S1473-3099(06)70580-1.
22. Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. 2008. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob. Agents Chemother. 52:3047-3051. http://dx.doi.org/10.1128/AAC.00103-08.
23. Dudhani RV, Nation RL, Li J. 2010. Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage. J. Antimicrob. Chemother. 65:1412-1415. http://dx.doi.org/10.1093/jac/ dkq134.
24. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. 1999. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 130:461-470.
25. National Kidney Foundation Kidney Disease Outcomes Quality Initiative. 2002. Part 5. Evaluation of laboratory measurements for clinical assessment of kidney disease. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. National Kidney Foundation, New York, NY.
26. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Johnson DW. 2001. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J. Chromatogr. B. Biomed. Sci. Appl. 761:167-175. http://dx.doi.org/10.1016/S0378- 4347(01)00326-7.
27. Li J, Milne RW, Nation RL, Turnidge JD, Coulthard K, Valentine J. 2002. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob. Agents Chemother. 46:3304-3307. http://dx.doi.org/10.1128/AAC.46.10.3304-3307.2002.
28. Birnboim HC, Doly J. 1979. A rapid alkaline extraction procedure for screening recombinant plasmid DNA. Nucleic Acids Res. 7:1513-1523. http://dx.doi.org/10.1093/nar/7.6.1513.
29. Hunt CA, MacGregor RD, Siegel RA. 1986. Engineering targeted in vivo drug delivery. I. The physiological and physicochemical principles governing opportunities and limitations. Pharm. Res. 3:333-344.
30. Stevens AJ, Martin SW, Brennan BS, McLachlan A, Gifford LA, Rowland M, Houston JB. 1995. Regional drug delivery II: relationship between drug targeting index and pharmacokinetic parameters for three non-steroidal anti-inflammatory drugs using the rat air pouch model of inflammation. Pharm. Res. 12:1987-1996. http://dx.doi.org/10.1023/A:1016212510900.
31. Couet W, Gregoire N, Gobin P, Saulnier PJ, Frasca D, Marchand S, Mimoz O. 2011. Pharmacokinetics of colistin and colistimethate sodium after a single 80-mg intravenous dose of CMS in young healthy volunteers. Clin. Pharmacol. Ther. 89:875-879. http://dx.doi.org/10.1038/clpt.2011.48.
32. He H, Li J, Nation RL, Jacob J, Chen G, Lee HJ, Tsuji BT, Thompson PE, Roberts K, Velkov T, Li J. 2013. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J. Antimicrob. Chemother. 68:2311-2317. http://dx.doi.org/10.1093/jac/dkt207.
33. Li J, Milne RW, Nation RL, Turnidge JD, Smeaton TC, Coulthard K. 2004. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J. Antimicrob. Chemother. 53:837-840. http://dx.doi.org/10.1093/jac/dkh167.
34. Gales AC, Jones RN, Sader HS. 2011. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09). J. Antimicrob. Chemother. 66:2070-2074. http://dx.doi.org/10.1093/jac/dkr239.
35. Imberti R, Cusato M, Villani P, Carnevale L, Iotti GA, Langer M, Regazzi M. 2010. Steady-state pharmacokinetics and BAL concentration of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 138:1333-1339. http://dx.doi.org/10.1378/chest.10-0463.
36. Conte JE, Jr, Golden JA, Kipps J, Zurlinden E. 2002. Intrapulmonary pharmacokinetics of linezolid. Antimicrob. Agents Chemother. 46:1475-1480. http://dx.doi.org/10.1128/AAC.46.5.1475-1480.2002.
37. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J. Appl. Physiol. (1985). 60:532-538.
38. Athanassa ZE, Markantonis SL, Fousteri MZ, Myrianthefs PM, Boutzouka EG, Tsakris A, Baltopoulos GJ. 2012. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med. 38:1779-1786. http://dx.doi.org/10.1007/s00134-012-2628-7.
39. Marchand S, Gobin P, Brillault J, Baptista S, Adier C, Olivier JC, Mimoz O, Couet W. 2010. Aerosol therapy with colistin methanesulfonate: a biopharmaceutical issue illustrated in rats. Antimicrob. Agents Chemother. 54:3702-3707. http://dx.doi.org/10.1128/AAC.00411-10.
40. W S Yapa S, Li J, Porter CJH, Nation RL, Patel K, McIntosh MP. 2013. Population pharmacokinetics of colistin methanesulfonate in rats: achieving sustained lung concentrations of colistin for targeting respiratory infections. Antimicrob. Agents Chemother. 57:5087-5095. http://dx.doi.org/10.1128/AAC.01127- 13.